Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Lotte Biologics is allocating fresh investments in its own home ground to build three new production plants. The leading pharma company is spending $3 billion for the new facilities that will be constructed in South Korea.
Lotte Biologics is aiming to complete the new factories by the year 2030, and the plan is to build a bio-industrial complex where it will house the three plants. The company is expecting a production capacity of 360,000 liters of anti-body medicines per year in Korea.
As per Pulse News, Lotte Biologic’s chief executive officer, Lee Won Jik, revealed the company’s mid and long-term plan when he attended the J.P. Morgan Healthcare Conference in San Francisco. At that time, he said that they would bolster their business competitiveness to become a major competitor in the contract development and manufacturing organization (CDMO) market. The company’s strategy to achieve this is to acquire assets and build new facilities.
To set its plan in motion, the firm will start the construction of its first plant in the Lotte Bio Campus production complex within the second half of this year. This first factory is set to operate for commercial production by 2027. As for the entire complex, it is expected to be completed in 2034.
Lotte Biologics planned this new investment after completing its acquisition of Bristol Myers Squibb’s manufacturing plant in Syracuse, New York. It purchased the facility for $160 million earlier this month as part of its strategy to expand overseas.
“Each plant will require approximately $1 billion in investment for a total of $3 billion invested by 2030,” Lee said during the presentation. The three plants will each have a 120,000-liter capacity, for a combined 360,000 liters.” Korea Joongang Daily quoted Lotte Biologics’ CEO as saying during the conference with regards to its latest investment in South Korea.
He added, “While the locations have not been announced, the bio company plans to start the construction of the first plant in the second half of this year. The first plant is set to start commercial manufacturing in 2027 after completing the facility in the second half of 2025. It aims to run all of three factories by 2034 and generate $3 billion in sales annually with a profit margin of 35 percent.”
